A Phase I Clinical Study of Dendritic Cell Vaccine against Measles for Patients Following Hematopoietic Cell Transplantation

A Phase I Clinical Study of Dendritic Cell Vaccine against Measles for Patients Following Hematopoietic Cell Transplantation - DC vaccine against Measles

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006471

Enrollment

Registered

2011-10-04

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-HCT patients

Interventions

until 6 weeks after DC vaccine against measles, 0.2 to 5 million DCs, single subcutaneous inoculation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provide signed, written informed consent. 2. be a post-HCT patient 3. Serum anti-measles antibody should be negative. 4. Have a Eastern Cooperative Oncology Group Performance Status (PS) of 0-2. 5. Have adequate liver, renal, and cardiac function.

Exclusion criteria

Exclusion criteria: 1. Have a recurrent or relapse of their diseases 2. Are pregnant or lactating. 3. Have psychiatric disorders that would interfere with consent, study participation, or follow-up. 4. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or pancreas.

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
serum-anti measles antibody titer	—

Countries

Japan

Contacts

Public ContactTadashi Kumamoto

Mie University Graduate School of Medicine Department of Pediatric and Developmental Science, Institute of Molecular and Experimental Medicine

tkumamjp@yahoo.co.jp059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026